Ann: Half Yearly Report and Accounts, page-22

From the internetFYI

Starpharma Reports Revenue Growth and Regulatory Milestone for DEP® SN38

​

• Starpharma’s adjusted revenue rose 65%, driven by research and product sales.
• FDA feedback boosts DEP® SN38’s potential, aiding Starpharma’s growth.

Starpharma Holdings Limited AU:SPL +9.09% ▲


Starpharma Holdings Limited reported a 65% increase in adjusted revenue for the half-year ending December 2024, driven by research revenue from Petalion Therapeutics and increased product sales. The company also achieved a 29% reduction in operating loss, attributed to the completion of several DEP® clinical programs. A significant regulatory milestone was reached with the FDA’s positive feedback on the DEP® SN38 clinical pathway, enhancing its potential for treating platinum-resistant ovarian cancer. This progress, alongside ongoing partnerships and asset optimization, positions Starpharma for future growth and stakeholder engagement.